Pages that link to "Q111610931"
Jump to navigation
Jump to search
The following pages link to E. William St. Clair (Q111610931):
Displaying 50 items.
- Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States (Q23911106) (← links)
- Association of Epstein-Barr virus with systemic lupus erythematosus - effect modification by race, age, and cytotoxic T lymphocyte-associate antigen 4 genotype (Q23911107) (← links)
- Solving the puzzle of autoimmunity: critical questions (Q28084677) (← links)
- Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis (Q28732725) (← links)
- Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (Q29616063) (← links)
- The calm after the cytokine storm: lessons from the TGN1412 trial (Q30481519) (← links)
- Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). (Q30993164) (← links)
- A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis (Q33212616) (← links)
- Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. (Q33342337) (← links)
- The use of analgesics in the management of pain in rheumatic diseases (Q33542921) (← links)
- Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. (Q33608644) (← links)
- A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial (Q33675468) (← links)
- Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group (Q33885648) (← links)
- Efficacy of remission-induction regimens for ANCA-associated vasculitis (Q34037683) (← links)
- Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. (Q34144779) (← links)
- Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis (Q34181975) (← links)
- Temporal correlation of antibody responses to different epitopes of the human La autoantigen (Q34243102) (← links)
- Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis (Q34287829) (← links)
- Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism (Q34329268) (← links)
- Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial (Q34458468) (← links)
- Progress in the treatment of rheumatoid arthritis (Q34458770) (← links)
- Interleukin-10: therapeutic prospects in rheumatoid arthritis (Q34494410) (← links)
- Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis (Q34500502) (← links)
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (Q34500921) (← links)
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial (Q34552451) (← links)
- Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial (Q34566883) (← links)
- Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases (Q34618142) (← links)
- Solid malignancies among etanercept‐treated patients with granulomatosis with polyangiitis (Wegener's): Long‐term followup of a multicenter longitudinal cohort (Q34628409) (← links)
- Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease (Q34781971) (← links)
- Tides of inflammation: impact of biologics. (Q34866152) (← links)
- Infliximab treatment for rheumatic disease: clinical and radiological efficacy (Q34963107) (← links)
- Challenges in the pursuit of immune tolerance. (Q34974448) (← links)
- Alpha1‐antitrypsin deficiency–related alleles Z and S and the risk of Wegener's granulomatosis (Q35067645) (← links)
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis (Q35109118) (← links)
- Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis (Q35168553) (← links)
- Treatment of early rheumatoid arthritis (Q35198221) (← links)
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement (Q35228543) (← links)
- Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis (Q35241994) (← links)
- Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States (Q35553206) (← links)
- Infliximab in active early rheumatoid arthritis (Q35553834) (← links)
- Interleukin 10 treatment for rheumatoid arthritis (Q35579058) (← links)
- Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis (Q35583154) (← links)
- Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures (Q35605666) (← links)
- Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). (Q35649141) (← links)
- IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis (Q35651433) (← links)
- Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis (Q35754787) (← links)
- Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy (Q35788326) (← links)
- Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (Q35798078) (← links)
- Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). (Q35835278) (← links)
- Peripheral CD5 B cells in antineutrophil cytoplasmic antibody-associated vasculitis (Q35835724) (← links)